drugset / Trial / NCT03193957

An Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in Subjects With Rheumatoid Arthritis

NCT03193957

Phase 2 Completed 50 enrolled Samsung Bioepis Co., Ltd.
NaSingle-groupOpen-labelOther

Summary

A study comparing the usability of the Autoinjector and Pre-filled Syringe of SB4 in Subjects with Rheumatoid Arthritis.

Timeline

Start
2017-05-15
Primary completion
2017-08-03
Completion
2017-09-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 50 mg/ml Subcutaneous

Indications